[go: up one dir, main page]

WO2025108664A1 - Analyse de la peau personnalisée et soins personnels - Google Patents

Analyse de la peau personnalisée et soins personnels Download PDF

Info

Publication number
WO2025108664A1
WO2025108664A1 PCT/EP2024/080635 EP2024080635W WO2025108664A1 WO 2025108664 A1 WO2025108664 A1 WO 2025108664A1 EP 2024080635 W EP2024080635 W EP 2024080635W WO 2025108664 A1 WO2025108664 A1 WO 2025108664A1
Authority
WO
WIPO (PCT)
Prior art keywords
active
skin
microbiome
personal care
consumer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/080635
Other languages
English (en)
Inventor
Chung-Ching Chu
Xiao CUI
Yining XU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Original Assignee
Unilever Global IP Ltd
Unilever IP Holdings BV
Conopco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unilever Global IP Ltd, Unilever IP Holdings BV, Conopco Inc filed Critical Unilever Global IP Ltd
Publication of WO2025108664A1 publication Critical patent/WO2025108664A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/148—Screening for cosmetic compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present invention relates to methods for providing skin analysis, and personalized personal care information based on that analysis, to consumers.
  • the phenotypic characteristics being measured are typically end products of the underlying mechanisms which are responsible for healthy skin and its appearance. In order to effectively create personalization in personal care, it is necessary to gain an insight into these underlying mechanisms. This requires an understanding of the skin microbiome and how to maintain its delicate balance.
  • the present inventors have recognized that there is a need to provide consumer personalized personal care route more precisely. Therefore, the present invention provides a method for providing skin analysis and personalized personal care information based on that analysis to a consumer. It is capable of providing the consumer personalized personal care routine with specific ingredient(s) that said consumer needs.
  • the present invention is directed to a method for providing skin analysis and personalized personal care information based on that analysis to a consumer, the method comprising: (a) building a reference database by linking the microbiome abundance data to the capability to produce one or more specific personal care ingredients; (b) receiving a sample of the skin microbiome, which is collected from a skin surface of the consumer; (c) determining the microbiome abundance data of said sample; (d) comparing the microbiome abundance data with the reference database; (e) providing a personalized personal care routine for said consumer based on the result of the comparison.
  • Microbiome refers to the diverse ecological community of commensal bacteria, fungi, viruses, and/or parasites that are associated with an organism.
  • Personal care means regulating and/or improving cosmetic qualities of the skin and/or hair. These qualities are subject to regulation and/or improvement both in healthy subjects as well as those which present diseases or disorders of the skin (such as atopic dermatitis, acne vulgaris, dandruff, dryness, psoriasis or lichen planus).
  • step (a) comprises the step of (a1) obtaining samples of the skin microbiomes, collected from a skin surface of N individuals, wherein N is at least 20; (a2) determining the microbiome abundance of said samples; and (a3) correlating the microbiome abundance data with the capability to produce one or more specific personal care ingredients.
  • the samples of the skin microbiomes may be obtained by non-invasive techniques such as tape stripping, scraping, swabbing or invasive techniques such as biopsy. It is preferable that sample of the skin microbiome is collected by non-invasive techniques, more preferably by tape stripping, swabbing, and/or buffer scrubbing.
  • N is preferably an integer of at least 50 and more preferably at least 100, even more preferably at least 200.
  • N is preferably an integer of less than 1,000,000, more preferably 100,000, even more preferably 10,000.
  • the skin surface of the consumer is preferably a facial skin surface, such as one or more of forehead, periorbital, cheek, perioral, chin, nose, or body skin surface for example hand, leg, underarm or scalp skin surface. More preferably, the skin surface of the consumer is preferably facial skin surface, and/or scalp skin surface.
  • the step of determining microbiome abundance data comprises the step of obtaining nucleic acid, preferably DNA.
  • the step of determining microbiome abundance data preferably comprises the step of quantitative polymerase chain reaction (qPCR), loop-mediated isothermal amplification (LAMP), microarray, or nucleic acid sequencing.
  • sequencing method may comprise whole genome sequencing, next generation sequencing, Sanger- sequencing, 16S rDNA sequencing and/or 16S rRNA sequencing, metagenomics sequencing, metatranscriptom ics sequencing. More preferably, the sequencing method is 16S rDNA sequencing and/or 16S rRNA sequencing.
  • the microbiome abundance data comprises the microbiome relative and/or absolute abundance of a panel of microorganism comprises strains of at least 4 and, preferably at least 7 of the following genera/species: (i) Acinetobacter spp., (ii) Corynebacterium spp., (iii) Cutibacterium acnes, (iv) Lactobacillus spp., (v) Staphylococcus epidermidis, (vi) Staphylococcus hominis, (vii) Staphylococcus capitis and (viii) Streptococcus spp.
  • the microbiome abundance data comprises the microbiome relative abundance of strains of 8 different skin microorganisms, representing each of the following genera/species: (i) Acinetobacter spp., (ii) Corynebacterium spp., (iii) Cutibacterium acnes, (iv) Lactobacillus spp., (v) Staphylococcus epidermidis, (vi) Staphylococcus hominis, (vii) Staphylococcus capitis and (viii) Streptococcus spp.
  • the capability to produce certain ingredient by the microbiome may be determined by multiplying abundance of the measured microorganisms by the average presence of the biosynthetic module of said microorganisms.
  • the presence of biosynthetic module in said microorganisms may be defined from genome sequences or public database on microbial metabolites.
  • the specific personal care ingredients may comprise skin hydration active, anti-inflammation active, skin barrier active, skin renewal active, anti-ageing active, depigmentation active, antiacne active, anti-dandruff active, anti-hair fall active, deodorants actives or a combination thereof.
  • the specific personal care ingredients comprise amino acids, vitamins, fatty acids, minerals, alpha hydroxyl acid, beta hydroxyl acid, carbohydrates, carboxylic acid, glycosaminoglycan, sphingolipids, humectants, steroids, peptides, polyamine, antioxidants, or precursor thereof.
  • Precursor as used herein refers to a compound capable of being converted into the active by the skin and/or the skin microbes and suitable for personal care use.
  • the microbiome abundance data of said samples may be classified to 3 to 50, preferably 8 to 25, even more preferably 10 to 20 groups according to the similarity of the microbiome abundance data.
  • the one or more specific personal care ingredients is correlated with specific group of the microbiome abundance data of said samples.
  • a sample of the skin microbiome is preferably collected from a skin surface of the consumer in a non-invasive manner.
  • this involves the use of a sterile cotton tip swab, which is rolled over the surface of the skin using moderate pressure and circular motions.
  • the sample of the skin microbiome is collected at the retail point of sale.
  • the skin surface of the consumer is preferably a facial skin surface such as one or more of forehead, periorbital, cheek, perioral, chin, and nose skin surfaces.
  • Step (c) determi nine the microbiome abundance data of said sample.
  • the step of determining microbiome abundance data comprises the step of obtaining nucleic acid, preferably DNA.
  • the step of determining microbiome abundance data preferably comprises the step nucleic acid sequencing.
  • the step of determining microbiome abundance data comprises the step of obtaining nucleic acid, preferably DNA, and step of nucleic acid sequencing.
  • sequencing method may comprise whole genome sequencing, next generation sequencing, Sanger- sequencing, 16S rDNA sequencing, 16S rRNA sequencing, metagenomics sequencing, and/or metatranscriptomics sequencing. More preferably, the sequencing method is 16S rDNA sequencing and/or 16S rRNA sequencing.
  • step (c) of the method of the invention comprises the step of obtaining the DNA from the sample of the skin microbiome and analysing the obtained DNA using a portable qPCR thermocycler.
  • a portable qPCR thermocycler suitable for use in the invention generally includes a housing, an amplification (or PCR) module, and a detection module.
  • the amplification module is configured to receive an input sample and defines a reaction volume.
  • the amplification module includes a heater such that the amplification module can perform a polymerase chain reaction (PCR) on the input sample.
  • the detection module is configured to receive an output from the amplification module and a reagent formulated to produce a signal that indicates a presence of a target amplicon within the input sample.
  • the amplification module and the detection module are integrated within the housing.
  • Preferred portable qPCR thermocyclers for use in the invention are of a size that can be held in one hand of a human operator.
  • Preferred portable qPCR thermocyclers for use in the invention weigh no more than 3.5 kg, more preferably no more than 3 kg, such as from 0.4 to 2.5 kg.
  • Portable qPCR thermocyclers suitable for use in the invention are commercially available, such as the FranklinTM (Biomeme Inc., Philadelphia, USA) which weighs less than 1kg and can test biological samples without the need for centrifugation, the use of frozen reagents, or a mains power source.
  • the device is capable of multiplex detection of up to three targets in each sample, where nine samples can be tested in a single run and results are delivered in less than an hour.
  • Other commercially available portable qPCR thermocyclers which may be used in the invention include the Mic qPCR cycler (Bio Molecular Systems Pty Ltd., Upper Coomera, AU) and the Liberty16 system (Ubiquitome Ltd, Auckland, NZ)
  • the microbiome abundance data comprises the microbiome abundance of a panel of microorganism comprises strains of at least Cutibacterium acnes and Staphylococcus epidermidis, more preferably at least 7 of the following genera/species: (i) Acinetobacter spp., (ii) Corynebacterium spp., (iii) Cutibacterium acnes, (iv) Lactobacillus spp., (v) Staphylococcus epidermidis, (vi) Staphylococcus hominis, (vii) Staphylococcus capitis and (viii) Streptococcus spp.
  • the microbiome abundance data comprises the microbiome abundance of strains of 8 different skin microorganisms, representing each of the following genera/species: (i) Acinetobacter spp., (ii) Corynebacterium spp., (iii) Cutibacterium acnes, (iv) Lactobacillus spp., (v) Staphylococcus epidermidis, (vi) Staphylococcus hominis, (vii) Staphylococcus capitis and (viii) Streptococcus spp.
  • step (c) comprises determining the microbiome abundance data and the capability to produce personal care ingredients of said sample.
  • the capability to produce certain ingredient by the microbiome may be determined by multiplying abundance of the measured microorganisms by the average presence of the biosynthetic module of said microorganisms.
  • the presence of biosynthetic module in said microorganisms may be defined from genome sequences or public database on microbial metabolites.
  • the microbiome data of said sample is uploaded for comparison, preferably through wired or wireless communication interfaces such as USB, Bluetooth® and/or Wi-Fi.
  • wired or wireless communication interfaces such as USB, Bluetooth® and/or Wi-Fi.
  • the comparing step is conducted by a program.
  • the step of comparing the microbiome abundance data with the reference database identifies the sample or group in the database which has the closest microbiome abundance data as the sample of the consumer.
  • Step (e) providing a personalized personal care routine for said consumer based on the result of the comparison
  • step (e) is executed within 90 minutes and more preferably within 40 minutes of receipt of the sample of the skin microbiome in step (b).
  • a personalized personal care routine may, for example, recommend the topical administration of a cosmetic composition which is designed for the consumer according to the result of the comparison.
  • a cosmetic composition containing the specific personal care ingredients or ingredients with similar bio-efficacy to which the microbiome has the capability to produce would be recommended.
  • a topical cosmetic composition for use in the invention may comprise one or more specific ingredients in a cosmetically acceptable vehicle.
  • the specific personal care ingredients may comprise skin hydration active, anti-inflammation active, skin barrier active, skin renewal active, anti-ageing active, depigmentation active, antiacne active, anti-dandruff active, anti-hair fall active, deodorants actives or a combination thereof.
  • the specific personal care ingredients comprise amino acids, vitamins, fatty acids, minerals, alpha hydroxyl acid, beta hydroxyl acid, carbohydrates, carboxylic acid, glycosaminoglycan, sphingolipids, humectants, steroids, peptides, polyamine, antioxidants, and/or precursor thereof.
  • Precursor as used herein refers to a compound capable of being converted into the active undergo one to three steps reaction and suitable for personal care use.
  • a topical cosmetic composition for use in the invention may additionally include one or more personal care actives which are designed to target specific skin attributes of the consumer, based on the image analysis or consumer desire described above.
  • personal care actives include vitamins, minerals and/or antioxidants, emollients, skin brightening agents, sunscreens, anti-irritants, exfoliating agents and mixtures thereof.
  • cosmetically acceptable means that the vehicles suitable for topical application to the skin, has good aesthetic properties, is compatible with any other ingredients, and will not cause any safety or toxicity concerns.
  • the vehicle may comprise an aqueous phase, an oil phase, an alcohol, a silicone phase, or a mixture thereof, and may be in the form of an emulsion.
  • Emulsions can have a range of consistencies including thin lotions (which may also be suitable for spray or aerosol delivery), creamy lotions, light creams, and heavy creams.
  • Topical cosmetic compositions for use in the invention may also be formulated in a single-phase carrier such as water and/or one or more water miscible organic liquids.
  • Topical cosmetic compositions for use in the invention may also be formulated in solid forms such as gels or sticks.
  • a profile of the consumer’s skin microbiome is also provided to the consumer, preferably at the retail point of sale.
  • the profile may indicate imbalances in the consumer’s skin microbiome, preferably, a list of one or more specific ingredients which are needed for the consumer according to the result of the comparison of the microbiome composition data of the tested consumer with those in the database is also provided to the consumer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne un procédé pour fournir une analyse de la peau, et des informations de soins personnels personnalisées sur la base de cette analyse.
PCT/EP2024/080635 2023-11-24 2024-10-30 Analyse de la peau personnalisée et soins personnels Pending WO2025108664A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2023133827 2023-11-24
CNPCT/CN2023/133827 2023-11-24
EP24151064 2024-01-10
EP24151064.3 2024-01-10

Publications (1)

Publication Number Publication Date
WO2025108664A1 true WO2025108664A1 (fr) 2025-05-30

Family

ID=93288887

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/080635 Pending WO2025108664A1 (fr) 2023-11-24 2024-10-30 Analyse de la peau personnalisée et soins personnels

Country Status (1)

Country Link
WO (1) WO2025108664A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200102600A1 (en) * 2017-03-10 2020-04-02 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US20210310054A1 (en) * 2013-06-18 2021-10-07 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US20220142560A1 (en) * 2020-11-06 2022-05-12 Johnson & Johnson Consumer Inc. Microbiome and metobolome clusters to evaluate skin health
WO2023280711A1 (fr) * 2021-07-05 2023-01-12 Unilever Ip Holdings B.V. Procédé d'évaluation de la peau

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210310054A1 (en) * 2013-06-18 2021-10-07 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US20200102600A1 (en) * 2017-03-10 2020-04-02 Prodermiq, Inc. Customized skin care products and personal care products based on the analysis of skin flora
US20220142560A1 (en) * 2020-11-06 2022-05-12 Johnson & Johnson Consumer Inc. Microbiome and metobolome clusters to evaluate skin health
WO2023280711A1 (fr) * 2021-07-05 2023-01-12 Unilever Ip Holdings B.V. Procédé d'évaluation de la peau

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHILLER KATARINA ET AL: "Skin Microflora and Bacterial Infections of the Skin", vol. 6, no. 3, 1 December 2001 (2001-12-01), US, pages 170 - 174, XP093174673, ISSN: 1087-0024, Retrieved from the Internet <URL:https://batavia.internal.epo.org/citenpl/citation/prod/pdf/c6cfbc68-68b3-3b08-a5fe-87ffb0ad0bf7.pdf> DOI: 10.1046/j.0022-202x.2001.00043.x *
GUENICHE AUDREY ET AL: "Advances in Microbiome-Derived Solutions and Methodologies Are Founding a New Era in Skin Health and Care", PATHOGENS, vol. 11, no. 2, 20 January 2022 (2022-01-20), pages 121, XP055943801, DOI: 10.3390/pathogens11020121 *
MANON BOXBERGER ET AL: "Challenges in exploring and manipulating the human skin microbiome", MICROBIOME, BIOMED CENTRAL LTD, LONDON, UK, vol. 9, no. 1, 30 May 2021 (2021-05-30), pages 1 - 14, XP021291750, DOI: 10.1186/S40168-021-01062-5 *

Similar Documents

Publication Publication Date Title
Shibagaki et al. Aging-related changes in the diversity of women’s skin microbiomes associated with oral bacteria
Troccaz et al. Mapping axillary microbiota responsible for body odours using a culture-independent approach
Fredrich et al. Daily battle against body odor: towards the activity of the axillary microbiota
Kong et al. Performing skin microbiome research: a method to the madness
Lam et al. Understanding the microbial basis of body odor in pre-pubescent children and teenagers
US20070196344A1 (en) Methods for identifying materials that can help regulate the condition of mammalian keratinous tissue
CN102177253A (zh) 测定皮肤样品的年龄范围
Gómez et al. Identification of species of Brucella using Fourier transform infrared spectroscopy
Seyfarth et al. Identification of yeast isolated from dermatological patients by MALDI‐TOF mass spectrometry
JP2011516061A (ja) 核酸を安定的に保管する新規皮膚遺伝子カードとこれを用いた遺伝子分析方法、並びにこの応用方法
Stöckel et al. Raman spectroscopic monitoring of the growth of pigmented and non-pigmented mycobacteria
CN110904207B (zh) 一种与皮肤老化表征相关的易感基因检测panel及其应用
CN103409519B (zh) 一种用于鉴别绵羊与山羊源性成分的基因探针
CN110753966A (zh) 基于皮肤菌群分析的定制化护肤产品和个人护理产品
Kourkoumelis et al. Nail Raman spectroscopy: A promising method for the diagnosis of onychomycosis. An ex vivo pilot study
CN105886645A (zh) 一种用于评估皮肤抗皱情况的引物和探针及试剂盒
Sandhu et al. A review of next generation sequencing technologies used in the evaluation of the skin microbiome: what a time to be alive
WO2020230007A1 (fr) Procédé de sélection de régimes, d&#39;ingrédients et de compositions de traitement de la peau
WO2025108664A1 (fr) Analyse de la peau personnalisée et soins personnels
Yang et al. Direct species identification of common pathogenic dermatophyte fungi in clinical specimens by semi-nested PCR and restriction fragment length polymorphism
Warshaw et al. Patients with negative patch tests: retrospective analysis of North American Contact Dermatitis Group (NACDG) data 2001-2016
Wittwer et al. Tapping the potential of intact cell mass spectrometry with a combined data analytical approach applied to Yersinia spp.: detection, differentiation and identification of Y. pestis
Harris et al. Laser-Capture Microdissection–Based RNA Sequencing for Profiling Mouse and Human Sebaceous Gland Transcriptomes
Thompson et al. ToF-SIMS studies of Bacillus using multivariate analysis with possible identification and taxonomic applications
WO2024125888A1 (fr) Analyse de la peau et soins de la peau personnalisés

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24798498

Country of ref document: EP

Kind code of ref document: A1